General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FAHYM
ADC Name
WO2024110905A1 ADC-C4
Synonyms
WO2024110905A1 ADC-C4
   Click to Show/Hide
Organization
BEIGENE, LTD. | BEIGENE SWITZERLAND GMBH
Drug Status
Investigative
Drug-to-Antibody Ratio
7.9
Structure
Antibody Name
undisclosed
Antigen Name
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
 Antigen Info 
Payload Name
ADC-C4 Payload
 Payload Info 
Linker Name
Linker of ADC2-51
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.018
nM
CVCL_1453
Lung small cell carcinoma, Small cell lung cancer
Half Maximal Effective Concentration (EC50) 
0.022
nM
CVCL_1559
Minimally invasive lung adenocarcinoma
Half Maximal Effective Concentration (EC50) 
2.291
nM
CVCL_1561
Lung papillary adenocarcinoma
Half Maximal Effective Concentration (EC50) 
> 100
nM
CVCL_0418
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.018 nM Positive B7H3 expression (B7H3+++/++)
Method Description
Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model Lung small cell carcinoma, Small cell lung cancer H1048 cells CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.022 nM High B7H3 expression (B7H3 +++)
Method Description
Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model Minimally invasive lung adenocarcinoma H358 cells CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.291 nM Positive B7H3 expression (B7H3+++/++)
Method Description
Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model Lung papillary adenocarcinoma H441 cells CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 100 nM Negative B7H3 expression (B7H3-)
Method Description
Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model Breast adenocarcinoma MDA-MB-453 cells CVCL_0418
References
Ref 1 Antibody drug conjugates